

## CERPI Survey Results to Fuel CERP 2.0

As a one-of-a-kind, industry leading program that exists to support trusted science, CERP has been committed to excellence since its inception. In keeping with the natural expansion of our program over time, we have recently begun to initiate a series of changes that intend to ensure its stability while maintaining excellent support for investigators. As we progress toward attaining 'CERP 2.0', we sought the advice of our CERPIs to critically examine the areas of most importance to our research community through a comprehensive survey. In the present article, we will discuss some key findings from the survey.

A total of 80% of CERPI Survey respondents indicated that they were highly satisfied with CERP (Figure 1). Additionally, the vast majority of respondents indicated that they have received our quarterly *CERPI Communiqué* newsletter without issues. We look forward to being able to continue to provide relevant articles, including recent NR/NAD+ publications, updates to ChromaDex, NAD+ news in the media, investigator highlights, among other topics as indicated in Figure 2.

Fig. 1. Overall Satisfaction with CERP (1 very dissatisfied, 5 very satisfied)





Fig. 2. Desired Topics in the CERPI Communiqué



As alluded to in the opening paragraph, CERP has noted a significant increase in the demand for research material. We believe this is predominantly driven by the desire to translate preclinical findings into clinical findings, expand upon promising findings from pilot studies through larger-scale clinical trials, and more generally, a growing interest in the role of NAD+ precursors in health and disease. While we are tremendously excited by the expansion of our program and the increase in demand, this reasonably necessitates that CERP evolve in order

## In This Issue

- CERP 2.0 and CERPI Survey Results
- NAD+ Science and News We Are Talking About
- Upcoming Conferences for the CERP Team & ChromaDex SAB



## Reminder

Do not forget to submit your progress report every six (6) months, or as stipulated in your MTA. An updated progress report is required when requesting additional material or submitting an MTA amendment. We will provide you with a progress report form to simplify the process.

Request forms at [cerp@chromadex.com](mailto:cerp@chromadex.com) for:

- Abstract, manuscript, poster, or presentation slides submissions
- Bulk or clinical material requests
- Requesting an amendment

## Do You Want Your Voice Heard?

As always, the CERP team is immensely interested in hearing the opinions and viewpoints of our investigators.

Therefore, we are happy to report that The CERPI Communiqué will now accept Letters to the Editor.

CERPis who wish to write a letter may email [cerp@chromadex.com](mailto:cerp@chromadex.com).

In the email, please be sure to clearly indicate your title, institution, and which article the letter is referring to.

The letter should preferably contain no more than 500 words.


We look forward to hearing from you!

to remain sustainable long-term. Therefore, our program will begin to include options to purchase clinical Niagen and placebo material for CERP applicants. In this regard, we asked for your thoughts on the future of CERP material provisions (Figure 3). We noted that respondents indicated that it was 'reasonable' for ChromaDex to:

- Provide research material, *in kind*, up to a specified amount for the duration of the study (77%).
- Provide clinical research material for pilot and small studies, while investigators involved in Phase II+ studies would be asked to purchase material (55%).
- Require investigators to pay for freight, including required duty and taxes for material (65%).
- Select clinical studies that align with our business direction and provide research material free of charge for studies, even if they are Phase II+ studies (52%).

Understanding which CERP advantages were perceived as most important from you was also informative! Unsurprisingly, most CERPis rated access to unpublished studies and technical advice to improve likelihood of study success as of 'high importance.' Other areas of importance included support for Investigational New Drug (IND) applications, providing networking opportunities with other CERPis, availability of high-quality material, and customer service as it relates to requests, orders, and communications (Figure 4). In addition, we were delighted to see that you agreed with the importance of maintaining scientific credibility through independent, investigator-initiated, third-party funded research. We hope that you take full advantage of these services offered by CERP.

### Reasonability for Changes to CERP



When asked about material for preclinical studies, the greatest likelihood for purchasing the bulk powder material was for novel NAD+ precursors and Niagen® (Figure 5). Based upon the interest for novel NAD+ precursors, these compounds will be made available upon request for preclinical research. As research with these compounds is in the early stages, we anticipate that we will make these compounds available, *in kind*, through an MTA. Additionally, we will begin to charge for isotopically labelled compounds, as there appears to be minimal demand, however, it takes extensive work to produce these materials. If you are considering incorporating novel NAD precursors or labeled compounds into your research project, please complete a CERP Preclinical application from the [CERP Webpage](#) or contact us at [cerp@chromadex.com](mailto:cerp@chromadex.com).

As it relates to the clinical material, interest was shown for purchasing the currently available 250 mg Niagen® capsules, as well as 500 mg Niagen® capsules, that would require the addition of vegetable magnesium stearate to manufacture (Figure 6). Though we do not plan to manufacture 500 mg Niagen® capsules at this time, we will consider for 2024.




Fig. 4.

### CERP Advantages




Fig. 5. Likelihood of Purchasing Materials for Preclinical Research





Fig. 6. Likelihood of Purchasing Niagen® Clinical Material



**CHROMADEX,  
EMPOWERED BY:**



## Did we miss your publication?

Please be sure to send your manuscripts to [cerp@chromadex.com](mailto:cerp@chromadex.com) prior to submission and keep us updated as you move through the publication process.

Want to easily introduce CERP™ to your scientific colleagues? Feel free to share this newsletter or have them scan our QR code.



Thank you to everyone that completed the survey. We will roll out CERP 2.0 in Q2 (April-June) this year, and plan to incorporate many of your suggestions. We will continue to provide material, *in kind* through an MTA, for most preclinical studies, initial pilot and small clinical studies (up to 500 bottles of active and placebo, each), and for novel compounds. We will move forward with asking CERPIs to pay for related shipping and import costs, and we will start providing clinical material at a discounted price for larger and continuation studies, through a modified MTA. We will require everyone that is using our material to apply through CERP, and we continue to strive to provide added value to all of our CERPIs. Thank you for your feedback. ■

## NAD+ Science & News We Are Talking About

### Q1 Publications

- [Boosting NAD ameliorates hematopoietic impairment linked to short telomeres in vivo](#)
- [Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study](#)
- [Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases](#)
- [Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin](#)
- [Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial](#)
- [Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease](#)

### Other News

Linked below, please find a webinar hosted by investment firm Ladenberg Thalmann's Healthcare Symposia Series, featuring Dr. Charalampos (Haris) Tzoulis, a renowned clinical neurologist and expert on movement disorders and neurodegeneration.

In this webinar, Dr. Tzoulis discusses his clinical experience with nicotinamide riboside (NR). He delves into the lack of treatment options for patients with neurodegenerative diseases, and speaks about the impact of NR in various studies. Through his participation in CERP, Tzoulis has led or is leading many clinical studies (including several on Parkinson's disease) that indicate encouraging results in hard-to-treat patient groups.

In addition, there's a live Q&A at the end of the presentation that you may find enlightening.

You can view the webinar here:

[https://us06web.zoom.us/webinar/register/WN\\_OwrUeGC0TAGVYKWJlcOI\\_g](https://us06web.zoom.us/webinar/register/WN_OwrUeGC0TAGVYKWJlcOI_g)

Simply register your name and email and you'll have immediate access.

### Newly Registered Clinical Trials

- [Nicotinamide Riboside Supplementation in Progressive Multiple Sclerosis \(Norseman\)](#)
- [Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients \(NARNIA\)](#)
- [Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid \(MINIRICO\)](#)

## We Hope to See You at the Following Conferences

**issn**  
international society of sports nutrition  
The ISSN - Why Go Anywhere Else?!

**The 20<sup>th</sup> Annual ISSN Conference**  
**June 15-17, 2023**  
Westin Fort Lauderdale Beach Resort  
321 North Fort Lauderdale Beach Blvd.  
Fort Lauderdale, FL USA 33304  
**EARN your CEUs:** NASM 14 CEUs, CDR 14, NSCA 1.4, ISSN 14, ACSM 14 CECs

ASN American Society for Nutrition  
Excellence in Nutrition Research and Practice  
www.nutrition.org

**NUTRITION 2023**  
Where the **Best** in Science & Health Meet  
July 22-25 • Boston, MA

**Diet and Optimum Health Conference**  
**PRECISION HEALTH:**  
**LIVING BETTER, LONGER**  
September 19 - 20, 2023

ChromaDex Scientific Advisory Board Member, Dr. Rudy Tanzi of Harvard University will be giving a talk on “Alzheimer’s Disease is a Genetically Complex and Heterogenous Innate Immune Disorder,” at

**AD/PD 2023**  
March 28 - April 1  
**GOTHENBURG**

**AD/PD™ 2023**  
ADVANCES IN SCIENCE & THERAPY

International Conference on  
Alzheimer’s and Parkinson’s Diseases  
and related neurological disorders  
March 28 - April 1, 2023 | Gothenburg, Sweden **+HYBRID**

## CERPI Communiqué, Volume 4, Issue 1, March 2023



# CERP

ChromaDex External Research Program

ChromaDex, Inc.  
10900 Wilshire Boulevard, Suite 600  
Los Angeles, California, USA 90024  
+1 (310) 388-6706  
[cerp@chromadex.com](mailto:cerp@chromadex.com)  
<http://www.chromadex.com/cerp>

Setting the Industry Standard for Excellence in Collaborative Research

Interested in learning more about how to develop intellectual property that industry would want to license or how to commercialize your ideas?

If so, ChromaDex has a dynamic Business Development Team that would love to talk with you. For more information, send an email to [cerp@chromadex.com](mailto:cerp@chromadex.com) with the subject line: Business Development, and we will get you connected.

Expand Your NAD+ Research Portfolio by including rarely studied NAD+ precursors. For more information send an email to [cerp@chromadex.com](mailto:cerp@chromadex.com) with the subject line: Novel NAD+ Precursors.

Special thanks to our CERPI Communiqué content contributors, editors, and reviewers:

Rebecca Idoine  
Jun Kwon  
Yasmeen Nkrumah-Elie, PhD  
Andrew Shao, PhD  
Heather Van Blarcom, JD